<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531725</url>
  </required_header>
  <id_info>
    <org_study_id>C0601</org_study_id>
    <nct_id>NCT01531725</nct_id>
  </id_info>
  <brief_title>MULTIcentric BElgium/NEtherlands PRO-Kinetic Safety and Efficacy Study</brief_title>
  <acronym>MULTIBENE</acronym>
  <official_title>6 Months Evaluation of the BIOTRONIK PRO-Kinetic Coronary Stent System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate safety and efficacy of the BIOTRONIK
      PRO-Kinetic coronary CoCr-stent in patients with single de novo lesions of native coronary
      arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PRO-Kinetic study is a multi-center, prospective, consecutive non-randomized study
      enrolling 200 patients with single de novo lesions in native coronary arteries meeting the
      entry criteria. Those who provide informed consent will be enrolled to receive the
      PRO-Kinetic stent. Telephone follow-up will be performed at 1 month for all enrolled
      patients. After 6 months 100 patients will have an angiographic follow-up and 100 patients
      will be checked by telephone again. Additionally, a clinical telephone follow-up will be
      performed in all patients after 12 months.

      This study is designed to yield data on the clinical safety and efficacy of the PRO-Kinetic
      stent in the coronary artery application. The Target Vessel Failure Rate after 6 months shall
      be below 18 % (max. 35 Serious Adverse Events and Expedited Events) to show a
      safety/performance profile that could be considered in the range of the currently available
      bare metal stent systems
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>at 180 days post procedure</time_frame>
    <description>Target vessel failure is defined as composite of revascularization, recurrent myocardial infarction, or cardiac death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>at 180 days post procedure</time_frame>
    <description>MACE is defined as a composite of death, myocardial infarction, target lesion revascularization and coronary artery bypass grafting.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>BMS implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent). Since it is a single arm study design, no patients are enrolled to a control arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Percutaneous coronary intervention</description>
    <arm_group_label>BMS implantation</arm_group_label>
    <other_name>PRO-Kinetic stent system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 18 years old.

          -  Eligible for percutaneous coronary intervention (PCI).

          -  Documented stable (Canadian Cardiovascular Society Classification [CCS] 1, 2, 3, or 4)
             or unstable (Braunwald type I, II, III and A, B or C) angina pectoris, or documented
             silent ischemia.

          -  Left ventricular ejection fraction (LVEF) &gt; 30% documented within the last 6 weeks.

          -  Acceptable candidate for coronary artery bypass graft surgery (CABG).

          -  Patient understands the study requirements and the treatment procedures and provides
             written Informed Consent on a form that has been approved the by local Institutional
             Review Board before any specific test of the study or procedure is performed.

          -  Willing to comply with all the specified follow-up evaluations.

          -  Single target vessels to be treated.

          -  Single target lesion to be treated.

          -  Target lesion must be completely coverable by one study stent.

          -  Total target lesion length &lt;20 mm based on a visual estimate.

          -  RVD of ≥ 2.0 mm to ≤ 5.0 mm based on a visual estimate.

          -  Target lesion diameter stenosis ≥ 50% and &lt; 100% based on a visual estimate.

          -  Target lesion has not undergone prior revascularization up to now.

          -  Target vessel has not undergone prior revascularization within the preceding 6 months.

          -  Patient has no child bearing potential, is not pregnant, or intends to become pregnant
             during the study.

        Exclusion Criteria:

          -  Planned treatment with any other PCI device in target vessel except the pre-dilatation
             balloon.

          -  MI within 72 hours prior to the index procedure and/or creatine kinase (CK) &gt; 2 times
             the local laboratory upper limits of normal, measured on the day of the index
             procedure, associated with elevated MB.

          -  The patient is in cardiogenic shock.

          -  Cerebrovascular Accident (CVA) within the past 6 months.

          -  Acute or chronic renal dysfunction (creatinine &gt; 2.0 mg/dl or &gt; 150 µmol/L).

          -  Contraindication to ASA or to clopidogrel.

          -  Known Thrombocytopenia (platelet count 100, 000/mm3).

          -  Active gastrointestinal (GI) bleeding within the past three months.

          -  Known allergy to stainless steel or cobalt chromium.

          -  Any prior true anaphylactic reaction to contrast agents.

          -  Patient is currently taking colchicine.

          -  Life expectancy of less than 24 months due to other medical conditions.

          -  Co-morbid condition(s) that could limit the patient's ability to participate in the
             study, compliance with follow-up requirements or impact the scientific integrity of
             the study.

          -  Currently participating in another investigational drug or device study that has not
             completed the primary endpoint or that clinically interferes with the endpoints of
             this study.

          -  Left main coronary artery disease (stenosis &gt; 50%), whether protected or unprotected.

          -  Target lesion site is ostial (within 3.0 mm of vessel origin).

          -  Target lesion and/or target vessel proximal to the target lesion is severely calcified
             by visual estimation.

          -  Target lesion involves a bifurcation that requires intervention (usually, side branch
             &gt;2 mm in diameter).

          -  Target lesion is totally occluded (100% stenosis usually associated with TIMI flow
             ≤1).

          -  Angiographic presence of probable or definite thrombus.

          -  Target vessel will be pre-treated with an unapproved device, directional or rotational
             coronary atherectomy, laser, cutting balloon or transluminal extraction catheter prior
             to stent placement.

          -  Prior coronary intervention using brachytherapy to any segment of the target vessel.

          -  Angiographic restenosis of any segment of the target vessel that has undergone prior
             percutaneous coronary intervention.

          -  Angiographic evidence of atherosclerotic disease with &gt; 50% diameter stenosis (by
             visual estimate) proximal or distal to the target lesion

          -  Prior surgical revascularization of the target vessel with a documented patent graft
             (either a saphenous vein or an arterial conduit).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Vermeersch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZNA Middelheim, Department Interventional Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maarten J. Suttorp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Antonius Hospital Nieuwegein</affiliation>
  </overall_official>
  <results_reference>
    <citation>Vermeersch P, Appelman Y, Horstkotte D, Richardt G, Boland J, Lalmand J, Coussement P, Castadot M, Janssens L, Agostoni P, Buysschaert I, Suttorp MJ. Safety and efficacy of the cobalt chromium PRO-Kinetik coronary stent system: results of the MULTIBENE study. Cardiovasc Revasc Med. 2012 Nov-Dec;13(6):316-20. doi: 10.1016/j.carrev.2012.09.006.</citation>
    <PMID>23164477</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <results_first_submitted>February 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 19, 2013</results_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>202 patients at 10 European sites have been enrolled.</recruitment_details>
      <pre_assignment_details>Not group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BMS Implantation</title>
          <description>BMS implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="202">5 patients with protocol violation were excluded.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>197 patients were considered for baseline analysis. 5 patients with protocol violation were excluded.</population>
      <group_list>
        <group group_id="B1">
          <title>BMS Implantation</title>
          <description>Patients with a BMS implanted.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>Target vessel failure is defined as composite of revascularization, recurrent myocardial infarction, or cardiac death.</description>
        <time_frame>at 180 days post procedure</time_frame>
        <population>Patients with follow up data available either 180 or 360 days post procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS Implantation</title>
            <description>BMS implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>Target vessel failure is defined as composite of revascularization, recurrent myocardial infarction, or cardiac death.</description>
          <population>Patients with follow up data available either 180 or 360 days post procedure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Events (MACE)</title>
        <description>MACE is defined as a composite of death, myocardial infarction, target lesion revascularization and coronary artery bypass grafting.</description>
        <time_frame>at 180 days post procedure</time_frame>
        <population>Patients with follow up available either 180 or 360 days post procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS Implantation</title>
            <description>BMS implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events (MACE)</title>
          <description>MACE is defined as a composite of death, myocardial infarction, target lesion revascularization and coronary artery bypass grafting.</description>
          <population>Patients with follow up available either 180 or 360 days post procedure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BMS Implantation</title>
          <description>BMS implantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Target lesion revascularization</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass graft</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Target vessel revascularization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations:
missing comparators
permission to conduct follow up visits by telephone
limited number of 197 patients allows an insight of the safety and efficacy of the device.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Vermeersch, MD, PhD</name_or_title>
      <organization>ZNA Middelheim Department Interventional Cardiology, Antwerpen, Belgium</organization>
      <phone>+32 3 280 3211</phone>
      <email>paul.vermeersch@zna.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

